Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus and Cyclosporine in Refractory Aplastic Anemia
NCT00319878Phase 2Unknown
- Sponsor
- Office of Rare Diseases Research
- Start
- May 2006
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in aplastic anemia, sponsored by Office of Rare Diseases Research. Primary endpoint: Safety and tolerability of sirolimus and cyclosporine at 6 months. Status: unknown.
02
Drugs
sirolimus
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT00319878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00319878.